Penetration enhancement of transdermal delivery--current permutations and limitations.
about
Treatment of autoimmune inflammation by a TLR7 ligand regulating the innate immune systemTransdermal protein delivery by a coadministered peptide identified via phage display.LANTCET: elimination of solid tumor cells with photothermal bubbles generated around clusters of gold nanoparticles.Synthesis and immunological characterization of toll-like receptor 7 agonistic conjugates.Microneedle/nanoencapsulation-mediated transdermal delivery: mechanistic insightsAdditive melanoma suppression with intralesional phospholipid-conjugated TLR7 agonists and systemic IL-2.Intravesical Toll-like receptor 7 agonist R-837: optimization of its formulation in an orthotopic mouse model of bladder cancer.How to overcome the limitations of current insulin administration with new non-invasive delivery systems.Sumatriptan iontophoretic transdermal system for acute treatment of episodic migraine.Safety evaluation of stamp type digital microneedle devices in hairless mice.Ketotifen Fumarate and Salbutamol Sulphate Combined Transdermal Patch Formulations: In vitro release and Ex vivo Permeation Studies.Effect of hydroxyl groups and rigid structure in 1,4-cyclohexanediol on percutaneous absorption of metronidazole.Investigation of effects of terpene skin penetration enhancers on stability and biological activity of lysozyme.Use of lipolanthionine peptide, a toll-like receptor 2 inhibitor, enhances transdermal delivery efficiencyA novel transdermal honokiol formulation based on Pluronic F127 copolymer.In Vivo Experimental Study of Noninvasive Insulin Microinjection through Hollow Si Microneedle Array
P2860
Q28484146-D50457DC-7C91-4A7F-A1E2-8282AADA90D2Q33237687-399C17E6-F5D5-478B-861F-0B4BB283ABD5Q33371962-B17016DF-3A25-436B-9CE3-9F0EA2A7B7B8Q34291783-F1884FA7-1833-4BB8-B7CF-B69865C2BE3BQ34609195-396FE100-CB74-48B3-8B59-4BDC256E3417Q34672618-A26854AF-552E-43E6-BCA9-2B3A619DCF70Q37423131-1164DD4B-FD23-44C7-9C05-1BD49188B393Q38309884-B19DAE27-D5FF-4FCF-B68A-EFB9EDA9E8E9Q38804198-CA73D689-906B-41E2-B539-38FB74A0C928Q40096330-B1DF2DE3-B494-4C11-89B1-EAABF3F47242Q41844637-2545F304-51CC-4407-B7A7-9E286756629DQ41945652-1A3E0D3C-96AE-42C2-B07D-28E8BDBC7F2DQ41988211-EB568397-FACD-45A4-8A4B-E110193CE88BQ42733178-139E1D9C-C0FE-4868-A809-E23068842F13Q43154126-4EAFC050-5F81-4B41-B0A1-2E4DD25B3ADAQ58577160-A5F3C940-3C15-4CEC-93F1-7A1E1B9C99FA
P2860
Penetration enhancement of transdermal delivery--current permutations and limitations.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Penetration enhancement of transdermal delivery--current permutations and limitations.
@ast
Penetration enhancement of transdermal delivery--current permutations and limitations.
@en
type
label
Penetration enhancement of transdermal delivery--current permutations and limitations.
@ast
Penetration enhancement of transdermal delivery--current permutations and limitations.
@en
prefLabel
Penetration enhancement of transdermal delivery--current permutations and limitations.
@ast
Penetration enhancement of transdermal delivery--current permutations and limitations.
@en
P2093
P1476
Penetration enhancement of transdermal delivery--current permutations and limitations.
@en
P2093
Carryn H Purdon
Chad G Azzi
Eric W Smith
Howard I Maibach
P304
P356
10.1615/CRITREVTHERDRUGCARRIERSYST.V21.I2.20
P577
2004-01-01T00:00:00Z